Table 1.

Current VEGF/KDR (kinase-insert-domain-containing receptor) anti-angiogenic targets in clinical trials

Drug	Drug target	Disease target	Clinicaltrials.gov ID	Phase	Number patients	Relevant clinical study
Pazopanib	VEGFR tyrosine kinase inhibitor	AMD	NCT00612456 NCT01134055	2, Completed 2009     2b	70 510	Danis R, et al. Br J Ophthalmol 2014;98:172–178
TG100801	VEGF tyrosine kinase inhibitor	AMD, PDR	NCT00414999	1, Completed	44
TG100801	Same	AMD	NCT00509548	2, Terminated early	Terminated after 7 due to corneal deposits
OPT-302	VEGFR-3	AMD	NCT02543229	1	Enrolling 50
Regorafenib	Receptor tyrosine kinase VEGFR2-TIE2	AMD	NCT02222207	2	52
rAAV.sFlt-1	Flt1	AMD	NCT01494805	1 and 2	40	Rakoczy EP, et al. Lancet. 2015;386(10011):2395–403.
PAN-90806	Anti-VEGFR	AMD	NCT02022540	1	50
Squalamine lactate	VEGF	AMD RVO PDR	NCT01678963 NCT02614937 NCT01769183	2     1 and 2     2	142   20     6
Abicipar Pegol (AGN-150998)	Anti-VEGF	AMD DME	NCT01397409 NCT02181517 NCT02181504 NCT02462928 NCT02186119	2     2     2     3     2	271   25   25 900, R 151
PF582	Anti-VEGF	AMD	NCT02121353	1 and 2	25
EYE001	Anti-VEGF Pegylated Aptamer	AMD	NCT00021736	2 and 3	540
AL-39324	Inhibit VEGFR and PDGFR	AMD	NCT00992563	2	35
LHA510	VEGFA-inhibitor	AMD	NCT02076919 NCT02355028	1     2	135
X-82	VEGF and PDGF inhibitor	AMD	NCT02348359 NCT01674569	2, R     1 and 2	132   35
ESBA1008	Anti-VEGF	AMD	NCT01304693	1 and 2	376
BCD-021	Anti-VEGF	AMD	NCT02450981	1	10
LMG324	Anti-VEGF	AMD	NCT02398500	1 and 2	25, Terminated
TK001	Anti-VEGF	AMD	NCT02613559	1	27,R
ORA102		AMD	NCT00745511	1 and 2	96
RG7716	Anti-VEGFA	AMD	NCT02484690	2	271
AGN211745	VEGFR-1 siRNA	AMD	NCT00395057	2	138, Terminated
PTK787 (Vatalanib)	Tyrosine kinase inhibitor targets VEGFR	AMD	NCT00138632	1 and 2	50

Abbreviations: R= recruiting; AMD = neovascular age-related macular degeneration; DME = diabetic macular edema; PDR = proliferative diabetic retinopathy; RVO = retinal vein occlusion